Skip to main content
Vesalius Biocapital closes 3rd fund at more than $72.7M
5/19/2017

Vesalius Biocapital, a Luxembourg-based biotech venture firm, has obtained over $72.7 million in the first closing of its third fund, VBC III, bringing it closer to its target of approximately $167.8 million. The fund will invest in 10 to 15 late-stage European companies focused in the areas of medtech, diagnostics, drugs and digital health.

Full Story: